Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Life and Design Approved for use through 3/31/2007. OMB 0651-0021 ATTORNEY'S DOCKET NUMBER U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE MC098YP TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1:5) DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/CA2004/002101 09 December 2004 12 December 2003 TITLE OF INVENTION CATHEPSIN CYSTEINE PROTEASE INHIBITORS APPLICANT(S) FOR DO/EO/US Michael Boyd, Cheuk Lau, Christophe Mellon, Bruno Roy, John Scheigetz, Vouy Linh Truong Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (PCT Article 31). A copy of the International Application as filed [35 U.S.C. 371(c)(2)] a. is attached hereto (required only if not communicated by the International Bureau). b. X has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. X have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)]. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].

Items 11 to 20 below concern other document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. An Application Data Sheet under 37 CFR 1.76. A substitute specification.

17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.

A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).

☐ A second copy of the published International Application under 35 U.S.C.154(d)(4).

Page	1	of 2

A power of attorney and/or change of address letter.

Other items or information:

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Florage Control of Submission Under 35-U Annoroxed for use through 3/31/2007. OMB 0651-0021 INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NU				
	MBER			
16/581692 PCT/CA2004/002101 MC098YP				
The following fees are submitted: CALCULATIONS PTO US	SE ONLY			
21. Basic national fee				
22. Examination fee (37 CFR 1.492(c))				
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0				
All other situations\$200				
23. Search fee (37 CFR 1.492(b)) If the written entiring of the ISA/US as the international proliminary enemination against a property and the control of the ISA/US as the international proliminary enemination and the control of the ISA/US as the international proliminary enemination and the control of t				
If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				
Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an				
International Searching Authority				
Previously communicated to the US by the IB				
TOTAL OF 21, 22 and 23= \$700.00	•			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or				
computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.				
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole number)				
- 100 = 0 /50 0 = 0 X \$250.00 \$0.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].				
CLAIMS NUMBER FILED NUMBER EXTRA RATE				
Total Claims 12 - 20 = 0 X \$50.00 \$0.00				
Independent Claims 1 - 3 = 0 X \$200.00 \$0.00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00				
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) = \$700.00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest				
claimed priority date (37 CFR 1.492(f)). +				
TOTAL NATIONAL FEE = \$700.00				
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.				
TOTAL FEES ENCLOSED = \$700.00				
Amount to be				
refunded: Amount to be				
charged:				
a. A check in the amount of \$ to cover the above fees is enclosed.				
b. Please charge my Deposit Account No. 13-2755 in the amount of \$700.00 to cover the above fees. A duplicate copy of this sheet is enclosed.				
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.				
SEND ALL CORRESPONDENCE TO:				
Customer No. 000210				
Patent Department, RY60-30				
P.O. Box 2000 SIGNATURE SIGNATURE				
Rahway New Jersey 07065-0970				
Nicole M. Beeler NAME				
DATE: June 6, 2006				
PHONE #: (732) 594-1077 45,194 REGISTRATION NUMBER				

10/581692

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES UN 2006 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

International Appln No.:	PCT/CA2004/002101
International Filing Date:	<u>09 December 2004</u>
Priority Date:	12 December 2003
Title:	CATHEPSIN CYSTEINE PROTEASE INHIBITORS
Inventors:	Michael Boyd, Cheuk Lau, Christophe Mellon, Bruno Roy, John Scheigetz, Vouy Linh Truong

MC098Y

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT June 6, 2006

EXPRESS MAIL NO. EL 989590447 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

Attorney Docket No.:

June 6, 2006